Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23199871 | 1.00 | PRKCA (0.41) | PRKCAPRKCDCYP2D6CYP1A2PKM | |
| SCHEMBL20278757 | 0.84 | GABBR2 (0.41) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL14576377 | 0.83 | RIPK1 (0.34) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL5362272 | 0.83 | RIPK1 (0.34) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL14611842 | 0.83 | RIPK1 (0.34) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL28922762 | 0.81 | PRKCA (0.40) | PRKCAPRKCDCYP2D6CYP1A2PKM | |
| SCHEMBL15300270 | 0.81 | GABBR2 (0.36) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL14878508 | 0.80 | RIPK1 (0.47) | CYP2D6RIPK1L3MBTL1AOC3 | |
| SCHEMBL1154991 | 0.80 | RIPK1 (0.47) | CYP2D6RIPK1L3MBTL1AOC3 | |
| SCHEMBL9023303 | 0.78 | RIPK1 (0.46) | TRPA1RIPK1AOC3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150349-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| EP-3681885-B1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3681885-B1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230390401-A1 | RAPIDLY RELEASED BIOORTHOGONAL CAGING GROUPS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-12-07 | — | — | US | disclosed |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230122024-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-20 | — | — | US | disclosed |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| US-20210107914-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3681885-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200216445-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-07-09 | — | — | US | disclosed |
| US-20200216445-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-07-09 | — | — | US | disclosed |
| WO-2019055877-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019055877-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20090312559-A1 | CATALYTIC ENANTIOSELECTIVE SILYLATIONS OF SUBSTRATES | NATIONAL INSTITUTES OF HEALTH, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT | 2009-12-17 | — | — | US | disclosed |
| WO-2007082026-A2 | CATALYTIC ENANTIOSELECTIVE SILYLATIONS OF SUBSTRATES | THE TRUSTEES OF BOSTON COLLEGE (US) | 2007-07-19 | — | — | WO | disclosed |
| US-5962462-A | COMPOUNDS WHICH INHIBIT THE ENTRY OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INTO TARGET CELLS; DELAYING THE ONSET OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS). | MERCK & CO., INC. (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1998025605-A1 | SPIRO-SUBSTITUTED AZACYCLES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216445-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | EP300, CREBBP, BRD3 | PRKCA 654/4885PRKCD 1643/4885CYP2D6 4835/4885 |
| US-20090312559-A1 | CATALYTIC ENANTIOSELECTIVE SILYLATIONS OF SUBSTRATES | LSS, COASY, CYP51A1 | PRKCA 4062/4885PRKCD 4121/4885CYP2D6 86/4885 |
| US-20240150349-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | EP300, CREBBP, BRD3 | PRKCA 654/4885PRKCD 1643/4885CYP2D6 4835/4885 |
| US-20230390401-A1 | RAPIDLY RELEASED BIOORTHOGONAL CAGING GROUPS | CBR3, CBR1, OR10J3 | PRKCA 4881/4885PRKCD 4879/4885CYP2D6 1063/4885 |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | EP300, CREBBP, BRD3 | PRKCA 654/4885PRKCD 1643/4885CYP2D6 4835/4885 |
| US-20210107914-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | PRKCA 890/4885PRKCD 815/4885CYP2D6 1746/4885 |
| US-20230122024-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | PRKCA 890/4885PRKCD 815/4885CYP2D6 1746/4885 |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | EP300, CREBBP, BRD3 | PRKCA 654/4885PRKCD 1643/4885CYP2D6 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.